What is Biofourmis?
Headquartered in Boston with a significant operational footprint in Singapore and India, Biofourmis specializes in technology-enabled care delivery. The company leverages advanced artificial intelligence to extend hospital-level care into the home environment. Its core platform is designed to integrate seamlessly with health systems, payers, and life science organizations, providing an end-to-end solution that spans from pre-surgical optimization to acute and post-acute care management. Following its strategic merger with CopilotIQ, the firm has further enhanced its capacity to deliver comprehensive, data-backed health outcomes, effectively reducing hospital readmissions and accelerating the drug development lifecycle.
How much funding has Biofourmis raised?
Biofourmis has raised a total of $561.1M across 7 funding rounds:
Private Equity
$1M
Series A
$5M
Series B
$35M
Debt
$150K
Series C
$100M
Series D
$320M
Series C
$100M
Private Equity (2016): $1M with participation from SpesNet and Eden Strategy
Series A (2017): $5M led by Aviva, The Northstar Group, and NSI Ventures
Series B (2019): $35M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Series C (2020): $100M backed by Softbank Capital, EDBI, MassMutual Ventures, Openspace Ventures, and Steamboat Ventures
Series D (2022): $320M with participation from Trevor Fetter, General Atlantic, and CVS Health
Series C (2025): $100M led by Edbi, Sequoia Capital, Massachusetts Mutual Life Insurance, Openspace Ventures, and SoftBank Corp
Key Investors in Biofourmis
General Atlantic
General Atlantic is a global growth equity firm that provides capital and strategic support to high-growth companies in sectors such as consumer, financial services, healthcare, life sciences, and technology.
CVS Health
CVS Health is a diversified healthcare company providing healthcare services, pharmacy care, health benefits, and consumer health solutions, focusing on improving access, affordability, and health outcomes.
Sequoia Capital
Sequoia Capital is a premier venture capital firm that takes a long-term view on investments, acting as an active, value-added partner to entrepreneurs and management teams across venture, growth, and late-stage opportunities.
What's next for Biofourmis?
With the recent influx of capital, Biofourmis is well-positioned to accelerate its international expansion and deepen its integration within the global healthcare ecosystem. The strategic focus will likely center on scaling its AI-driven infrastructure to meet the rising demand for virtual care and decentralized clinical research. By leveraging its partnerships with major health systems and insurance providers, the company aims to refine its predictive analytics capabilities, further cementing its role as a foundational player in the future of home-based, patient-centric healthcare delivery. The firm remains committed to driving digital transformation across the care continuum, ensuring that its technological advancements translate into measurable improvements in patient safety and operational efficiency.
See full Biofourmis company page
